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Strengths and limitations of this study
 ► The primary outcome is perinatal mortality and neo-
natal morbidity, not prolongation of pregnancy.
 ► This is the largest randomised trial comparing ato-
siban to placebo for women with threatened preterm 
birth.
 ► Over 40 hospitals in Europe will participate.
 ► Tocolysis is incorporated in daily routine as it has 
been the recommendation in many guidelines.
 ► It will prove to be a challenge in counselling patients 
to participate in a placebo controlled trial, especially 
in an acute setting.
AbStrACt
Introduction Preterm birth complicates >15 million 
pregnancies annually worldwide. In many countries, 
women who present with signs of preterm labour are 
treated with tocolytics for 48 hours. Although this delays 
birth, it has never been shown to improve neonatal 
outcome. In 2015, the WHO stated that the use of 
tocolytics should be reconsidered and that large placebo- 
controlled studies to evaluate the effectiveness of 
tocolytics are urgently needed.
Methods and analysis We designed an international, 
multicentre, randomised, double- blinded, placebo- 
controlled clinical trial. Women with threatened preterm 
birth (gestational age 30–34 weeks), defined as uterine 
contractions with (1) a cervical length of < 15 mm or (2) 
a cervical length of 15–30 mm and a positive fibronectin 
test or (3) in centres where cervical length measurement 
is not part of the local protocol: a positive fibronectin test 
or insulin- like growth factor binding protein-1 (Actim- 
Partus test) or (4) ruptured membranes, will be randomly 
allocated to treatment with atosiban or placebo for 
48 hours. The primary outcome is a composite of perinatal 
mortality and severe neonatal morbidity. Analysis will be 
by intention to treat. A sample size of 1514 participants 
(757 per group) will detect a reduction in adverse neonatal 
outcome from 10% to 6% (alpha 0.05, beta 0.2). A cost- 
effectiveness analysis will be performed from a societal 
perspective.
Ethics and dissemination This study has been approved 
by the Research Ethics Committee (REC) of the Amsterdam 
University Medical Centres, location AMC, as well as the 
REC’s in Dublin and the UK. The results will be presented 
at conferences and published in a peer- reviewed journal. 
Participants will be informed about the results.
trial registration number Nederlands Trial Register (Trial 
NL6469).
IntroduCtIon
Preterm birth, defined as birth before 37 
weeks’ gestation, is a major contributor to 
perinatal mortality and morbidity, compli-
cating over 15 million pregnancies world-
wide.1 2 Of all infant deaths before the age of 
5 years, more than one- third can be attributed 
to preterm birth.3 In addition, spontaneous 
preterm birth is the leading cause of neonatal 
morbidity, mostly due to respiratory imma-
turity, intracranial haemorrhage and infec-
tions.4 5 These conditions can have long- term 
neurodevelopmental sequelae such as cogni-
tive impairment, cerebral palsy and visual 
and hearing deficiencies. Preterm birth is 
one of the largest single contributors to the 
global burden of disease because of the high 
mortality early in life and the morbidity of 
lifelong impairment.6
Maternal administration of corticosteroids 
to accelerate fetal lung maturation is an 
effective treatment for women with threat-
ened preterm birth.7 Since steroids have 
their maximum effect if birth is delayed by 
48 hours, many obstetricians administer a 
tocolytic drug alongside the steroids to allow 
maximal steroid effect and facilitate trans-
port of the mother to a centre with neonatal 
intensive care unit facilities if needed. Several 
tocolytics are used, including β adrenoceptor 
agonists, cyclooxygenase inhibitors (COX), 
magnesium sulfate, calcium- channel blockers 
and oxytocin receptor antagonists. Though 
more or less effective in delaying delivery, 
no tocolytics used in obstetrical practice 
are proven effective in reducing neonatal 
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morbidity and mortality.8 9 None of the studies so far have 
been powered to show such an effect.
The two most commonly used tocolytic drugs, atosiban 
and nifedipine, showed comparable perinatal outcome 
in the APOSTEL 3 study.10 However, neonatal mortality 
was higher in the nifedipine group, although not signif-
icant (5.4% vs 2.4% relative risk (RR) 2.20; 95% CI 0.91 
to 5.33).
The oxytocin receptor antagonist atosiban has fewer 
maternal side effects in head to head comparison with 
alternative drugs,11 and showed similar effectiveness in 
delaying birth compared with ritodrine.12 In placebo- 
controlled trials, a Cochrane review showed that atosiban 
did not reduce perinatal mortality (RR 2.25, 95% CI 0.79 
to 6.38; two studies with 729 infants) or major neonatal 
morbidity,13 although the quality of this review has been 
questioned.14
One explanation might be that since spontaneous 
preterm birth is associated in 40%–70% of cases with 
chorioamnionitis,15 16 tocolysis may prolong fetal expo-
sure to an infectious environment, which may worsen 
neonatal outcome.
Perinatal outcome has also markedly improved over the 
last few decades, in part due to postnatal interventions 
such as exogenous surfactant treatment which reduces 
mortality and respiratory morbidity in preterm infants.17 
This might also limit the potential benefit of tocolytics.
Worldwide, practice varies widely. Several large insti-
tutions in countries like Canada, Scotland and Ireland, 
rarely use tocolytics, while in the USA, COX (indometh-
acin) and calcium channel blockers (nifedipine) are 
popular. In Europe, nifedipine and the oxytocin antago-
nist, atosiban, are both widely used.
In conclusion, current widespread use of tocolytic 
drugs for this indication is not supported by the available 
evidence. The primary goal of tocolysis should not be 
prolongation of pregnancy, but improvement of neonatal 
outcome. This view is supported by the WHO, as they 
state in their 2015 guidelines on preterm birth that the 
effectiveness of tocolytics is not proven, and that placebo- 
controlled studies are urgently needed.18 Based on the 
results of the APOSTEL 3 study,10 the associated edito-
rial,19 and its safety profile we chose to evaluate atosiban 
in the APOSTEL 8 study.
objective
To test the hypothesis that tocolysis with atosiban in late 
preterm birth (30–34 weeks) reduces neonatal mortality 




We will conduct an international, multicentre, double- 
blind, randomised, placebo- controlled clinical trial, 
performed in The Netherlands, UK and Ireland.
Participants/eligibility criteria
Women, aged ≥18 years, with threatened preterm birth 
and a gestational age between 30+0 and 33+6 weeks are 
eligible. Threatened preterm birth is defined as uterine 
contractions with
1. A cervical length of <15 mm or
2. A cervical length of 15–30 mm and a positive fibronec-
tin test or
3. In centres where cervical length measurement is not 
part of the local protocol: a positive fibronectin test 
or insulin- like growth factor binding protein-1 (Actim- 
Partus test) or
4. Ruptured membranes.
These inclusion criteria are based on the results and 
conclusions of the APOSTEL 1 study20 and current guide-
lines within the Netherlands and the UK. Moreover, our 
previous APOSTEL 3 study, with resembling inclusion 
criteria, showed that half of the women with these criteria 
deliver within 7 days,10 validating this definition of women 
at high risk for preterm birth. In addition, the sample 
size of expected adverse neonatal outcome in the gesta-
tional age group of 30–34 weeks, was calculated from the 
APOSTEL 3 study.
This study was designed in a pragmatic fashion, in order 
for the results to be applicable in the current clinical 
practice. As most national guidelines and local protocols 
propose treatment for threatened preterm birth in both 
singleton and multiple pregnancies, as well as women 
with ruptured membranes, all these categories of patients 
are eligible for the study.
Women with a contraindication for tocolysis, signs 
of fetal distress, clinical signs of intrauterine infection, 
previous treatment for threatened preterm birth with 
corticosteroids in the current pregnancy and known fetal 
chromosomal or severe structural abnormalities are not 
eligible.
Procedures, recruitment, randomisation and collection of data
Potential participants will be identified by the local 
research co- ordinators and/or the staff of participating 
hospitals. Women eligible for the trial will be counselled 
by doctors, midwifes or research nurses trained in ‘good 
clinical practice’, and will be given a patient information 
form to read. Those who wish to participate, will be asked 
to give for written informed consent and are registered 
within the central trial database. Randomisation will be 
performed by using sequentially numbered medication 
packs available in each centre. Only the independent data 
manager has access to the computer- generated randomi-
sation list in which the medication numbers are linked 
with atosiban or placebo. Treatment allocation is blinded 
to investigators, participants, clinicians and research coor-
dinators. Randomisation will be balanced with varying 
block sizes of 2 and 4, and stratified by centre.
At study entry, baseline demographic, prior obstetric 
and medical history will be recorded into the web- based 
case report form accessible through a secure central 
website (Castor Electronic Data Capture, Ciwit B.V.).21 
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Details of delivery, maternal and neonatal assessments 
during pregnancy and postpartum period will be recorded 
on the same system. All data will be coded, processed and 
stored with adequate precautions to ensure patient confi-
dentially. This is described in a separate data manage-
ment plan.
Interventions
Participants are allocated to atosiban or matching placebo 
(0.9% saline) for 48 hours. The medication will be admin-
istered by a bolus injection of 6.75 mg/0.9 mL in 1 min 
followed by a continuous infusion of 18 mg/hour for 
3 hours followed by a continuous infusion of 6 mg/hour 
for the remaining 45 hours. Participating women will 
otherwise be treated according to local protocol based on 
national guidelines, including corticosteroids MgSO4 for 
neuroprotection and antibiotics if needed.
outcome measures
Outcome parameters are in line with the core outcome 
set for studies on prevention of preterm birth defined by 
members of GONet and the Core Outcomes in Women’s 
health (CROWN) initiative ( www. crown- initiative. org).22
The primary outcome measure is a composite of 
adverse perinatal outcome composed of perinatal in- hos-
pital mortality and six severe perinatal morbidities: bron-
chopulmonary (BPD), periventricular leucomalacia 
(PVL) >grade 1, intraventricular haemorrhage >grade 
2, necrotising enterocolitis (NEC) ≥stage 2, retinopathy 
of prematurity >grade 2 or needing laser therapy, and 
culture proven sepsis.
The diagnosis of BPD will be made according to the 
international consensus guideline as described by Jobe 
and Bancalari.23 PVL >grade 1 and intraventricular haem-
orrhage >grade 2 will be diagnosed by repeated cranial 
ultrasound according to the guidelines on neuroimaging 
described by de Vries et al24 and Ment et al.25 NEC ≥stage 2 
will be diagnosed according to Bell et al.26 Culture proven 
sepsis is diagnosed on the combination of clinical signs 
and positive blood cultures. The components of the 
composite adverse perinatal outcome will also be assessed 
separately.
Secondary infant outcomes will be birth within 
48 hours, time to birth, gestational age at birth, birth 
weight, number of days on invasive mechanical ventila-
tion, length of neonatal intensive care unit (NICU) stay, 
convulsions, asphyxia, meningitis, pneumothorax until 
hospital discharge.
Maternal outcomes will be mortality, infection of inflam-
mation and harm to mother from interventions (side 
effects). Side effects are defined as admission to intensive 
care, anaphylactic shock, dyspnoea, hypotension (leading 
tocardiotocography abnormalities), liver test abnormali-
ties (elevated aspartate aminotransferase (ASAT) or 
alanine aminotransferase (ALAT)), general side effects 
(nausea, vomiting, headache), postpartum haemorrhage 
defined as >500 mL blood loss and maternal mortality.
We will ask informed consent to approach the parents 
for long- term follow- up of the children. We intend, 
subject to funding, to use standardised questionnaires at 
2 and 5 years of age.
Maternal quality of life will be assessed at randomisation 
and at 3 months baby corrected age using the EuroQol 
(EQ- 5D- 5L) questionnaire. This consists of five dimen-
sions (mobility, self- care, usual activities, pain/discom-
fort, anxiety/depression) that are rated using five levels 
(no problems, slight problems, moderate problems, 
severe problems, extreme problems).
Societal costs will be assessed using adapted versions of 
the iMTA Medical and Productivity Cost Questionnaires 
at 3 months corrected baby age. Cost data include costs of 
the intervention, other healthcare utilisation, patient and 
family costs and costs of productivity losses.
Withdrawal of subjects
Participants can cease study treatment at any time for any 
reason if they wish to do so. Unless they refuse to allow 
further data collection, such participants will continue to 
be followed- up and will be analysed in the group to which 
they were originally allocated. Participants who decline 
follow- up will have no further trial data collected. Any 
results collected up to the point at which they decline 
follow- up will be analysed. Study medication will be discon-
tinued in patients with signs of intrauterine infections or 
signs of fetal distress (abnormal CTG, meconium stained 
amniotic fluid). Data of such participants will continue 
to be analysed. Further management will be left to the 
expertise of the responsible clinician. The responsible 
clinician can contact a perinatologist from the project 
group in case of suspected side effects or other medical 
problems. If necessary, treatment will be discontinued.
Monitoring and safety
An independent data safety monitoring board (DSMB) 
will focus on both effectiveness and safety. Serious adverse 
events (SAEs) will be collected from the first study- related 
procedure until 3 months after delivery. All SAEs will be 
reported to the DSMB within 7 days. Whenever there 
is proof of effectiveness (at interim analysis) or safety 
issues (increased (serious) adverse events in one of the 
two treatment arms) the DSMB will advise whether the 
trial should be stopped or continued. The DSMB will 
be blinded when first analysing the data, but unblinded 
before reaching a decision.
The advice(s) of the DSMB will only be sent to the 
sponsor of the study. Should the sponsor decide not to 
fully implement the advice of the DSMB, the sponsor 
will send the advice to the reviewing Medical Ethics 
Committee, including a note to substantiate why (part of) 
the advice of the DSMB will not be followed.
A formal interim analysis is planned after data collec-
tion of 500 and of 1000 women. At these interim anal-
yses, the Haybittle- Peto alpha spending function will be 
used, which means that an effect at interim with a p value 
<0.001 is considered statistically significant.
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Sample size
Based on the APOSTEL 3 data, the proportion of adverse 
perinatal outcome in women randomised between 30 and 
34 weeks’ gestation and treated with atosiban was 6%.10 
To show a 40% reduction (10% in the placebo group to 
6% in the atosiban group), we need to randomise 1438 
women (beta error 0.2; alpha error 0.05). Assuming a 5% 
drop- out or loss- to follow- up rate, we will randomise 1514 
women (757 in each arm).
Statistical analysis
Data analysis
Data analysis will be performed according to the intention- 
to- treat principle. In the baseline table, categorical vari-
ables will be expressed as a number with the percentage 
of the total allocation arm. Continuous variables will be 
presented as mean with SD, as geometric mean with 95% 
CI or as median with IQR, whichever appropriate.
The main outcome ‘adverse neonatal outcome’ will be 
assessed on the infant level, using a log- binomial gener-
alised estimating equations model to take into account 
the correlation of outcomes in multiples, resulting in an 
RR with accompanying 95% CI. To account for stratified 
randomisation by centre, we will also take centre into the 
model if the model converges.27 We will account for inter-
dependence between outcomes in multiple pregnancies 
by considering the mother as a cluster variable.28
The other secondary outcome measures on the child 
level will be analysed similar to the primary outcome 
measure. Outcomes on the maternal level will be assessed 
by using a binomial regression model with log- link func-
tion. When a statistically significant difference in primary 
outcome is found between both groups, we will calculate 
the number needed to treat. Time to delivery will be eval-
uated by Kaplan- Meier estimates and Cox proportional 
hazard analysis, taking into account the different dura-
tions of gestation at study entry, and will be tested with 
the log rank test. A p value of <0.05 will be considered to 
indicate statistical significance.
Subgroup analyses
The following subgroup analyses are planned:
1. Singleton versus multiple pregnancy.
2. Cervical length <15 mm versus cervical length 15–
30 mm and a positive fibronectin test (or no cervical 
length measurement and a positive fibronectin test or 
Partus test).
3. Ruptured or unruptured membranes at entry.
4. Previous preterm birth.
Sensitivity analysis
A sensitivity analysis will be performed excluding multiple 
pregnancies and pregnancies complicated by preterm 
premature rupture of membranes.
To assess whether a subgroup effect is present, we will 
add an interaction term between the subgrouping vari-
ables and the treatment allocation to the regression 
model. When an interaction term is statistically significant 
(p<0.05), we will estimate the treatment effect within 
strata of the subgrouping variable.
Details of the statistical analysis will be describes in 
separate statistical analysis plan that will be completed 
before data lock.
Cost-effectiveness analysis
The cost- effectiveness analysis will be done according 
to the intention- to- treat principle. Missing cost and 
effect data will be imputed using multiple imputation 
according to the Multivariate Imputation by Chained 
Equations (MICE) algorithm developed by Buuren.29 
Rubin’s rules will be used to pool the results from the 
different multiply imputed datasets. Bivariate regression 
analyses will be used to estimate cost and effect differ-
ences between atosiban and placebo while adjusting for 
confounders if necessary. Incremental cost- effectiveness 
ratios (ICERs) will be calculated by dividing the differ-
ence in the mean total costs between the treatment 
groups by the difference in mean effect between the 
treatment groups. Bias- corrected and accelerated boot-
strapping with 5000 replications will be used to estimate 
statistical uncertainty. Uncertainty surrounding ICERs 
will be graphically presented on cost- effectiveness planes. 
Cost- effectiveness acceptability curves will be estimated 
showing the probability that atosiban is cost- effective in 
comparison with placebo for a range of different ceiling 
ratios thereby showing decision uncertainty. Sensitivity 
analyses will be performed to assess the robustness of the 
results using different assumptions regarding costs and 
effects.
Patient and public involvement
The preterm birth research line of the Dutch consortium 
is in close collaboration with two Dutch patient associa-
tions, the Vereniging van Ouders van Couveusekinderen 
(VOC, freely translated to society of parents of children 
admitted to NICU) and the Nederlandse Vereniging 
van Ouders van Meerlingen (freely translated to Dutch 
society of parents of multiples). They are involved in the 
design of new studies, updated on progress of running 
trials and informed of study results. Project members are 
invited speakers at yearly conferences of these societies 
to present on the progress of our preterm birth research 
line. At these conferences, surveys are being performed 
on patient preferences on study ideas. Tocolysis was 
deemed an important research issue. Both associations 
have written support letters to the funding agency ZonMw 
(The Netherlands organisation for health research and 
development) for the APOSTEL 8 study.
A project panel of parents who experienced a sponta-
neous preterm birth consisting of six couples was involved 
in the design of our study. A survey was performed during 
the design of the study among members of the closed 
Facebook group of the VOC, to address questions on 
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The Dutch consortium has a website where it publishes 
all results of completed studies, and publishes the proto-
cols of currently recruiting studies.
Presentations will be held at yearly conferences at 
patient organisations and updates on research are being 
published in the journal of the VOC.
Ethics and dissemination
The Research Ethics Committee (REC) at the 
Amsterdam University Medical Centres, location AMC, 
approved this study. Additional regional approval was 
obtained for the remaining participating hospitals in 
The Netherlands. Furthermore, the study was approved 
by the REC of the National Maternity Hospital in 
Dublin, Ireland, and the REC of East Midlands—Derby 
in the UK. Protocol amendments will be communicated 
to a relevant parties. This trial is registered with the 
Nederlands Trial Register.
A manuscript with the results of the primary study 
will be published in a peer- reviewed journal. A separate 
manuscript will be written on the cost- effectiveness anal-
ysis. The results of this clinical trial will be presented at 
conferences and disseminated through publication in a 
peer- reviewed journal.
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